PT  - JOURNAL ARTICLE
AU  - Anne Weiss
AU  - Franck Touret
AU  - Cecile Baronti
AU  - Magali Gilles
AU  - Bruno Hoen
AU  - Antoine Nougairède
AU  - Xavier de Lamballerie
AU  - Morten Otto Alexander Sommer
TI  - Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variant
AID  - 10.1101/2021.04.26.441457
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.04.26.441457
4099  - http://biorxiv.org/content/early/2021/04/26/2021.04.26.441457.short
4100  - http://biorxiv.org/content/early/2021/04/26/2021.04.26.441457.full
AB  - SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide is effective against the D614G, B.1.1.7 and B.1.351 variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.Competing Interest StatementAW and MOAS have shares or options in UNION therapeutics. All other authors have no competing interests to declare.